 |
|
Gene variant boosts risk of fatty liver disease, scientists discover
September 26, 2008Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.
They also found that Hispanics are more likely to carry the gene variant responsible for higher liver-fat content than African-Americans and Caucasians.
The new findings, published online today in the journal Nature Genetics, provide a gene-based explanation for the results of a 2004 UT Southwestern-led study that determined that the propensity to develop nonalcoholic fatty liver disease differs among ethnic groups, with a higher percentage of Hispanics developing the disorder than African-Americans or Caucasians.
"A single variation in the PNPLA3 gene was strongly associated with hepatic fat content, even after adjusting for other factors, such as obesity, diabetes status and alcohol intake," said senior study author Dr. Helen Hobbs, director of the Eugene McDermott Center for Human Growth and Development and an investigator for the Howard Hughes Medical Institute at UT Southwestern.
"Sequence variations in this gene explain much of the increased propensity of Hispanics to accumulate excess liver fat," she said.
Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries, and its incidence is growing. Previous UT Southwestern research has shown that it may affect as many as one-third of adults in America.
"The gene variations we have identified might provide a way to predict who is most at risk for developing fatty liver disease and liver injury in response to environmental stresses such as obesity or infection," said Dr. Jonathan Cohen, professor of internal medicine in the McDermott Center and one of the authors of the study.
NAFLD results from the accumulation of triglycerides in the liver and is associated with metabolic disorders such as insulin resistance, obesity, diabetes and high cholesterol - many of the conditions that contribute to heart disease. It can also lead to liver inflammation, cirrhosis and liver cancer. Approximately 10 percent of liver transplants performed in the U.S. are for cirrhosis related to NAFLD, according to the researchers.
Treatments for NAFLD include weight loss, exercise, reducing alcohol intake and improved diabetes control.
"Knowing who is at increased risk of developing liver disease could aid physicians in encouraging their patients to make lifestyle changes or take other preventive measures to help mitigate their underlying genetic risk for the disorder," said Dr. Cohen, holder of the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.
The new findings come out of the Dallas Heart Study, an 8-year-old groundbreaking investigation of cardiovascular disease that involves a large multiethnic group of participants. The
$12 million study investigates the links between genetics, lifestyle and the risks for heart disease.
As part of the Dallas Heart Study, more than 3,500 individuals from Dallas County provided blood samples in 2000 for DNA isolation and other tests. Each participant also underwent multiple body scans with magnetic resonance imaging and computed tomography to examine the heart and other organs. Along with discovering new genetic ties to differences in blood levels of cholesterol and triglycerides, the researchers have used this information to identify new drug targets for the prevention and treatment of heart disease.
Data-gathering for the new study on fatty liver disease took advantage of a unique aspect of the Dallas Heart Study. Researchers with the study were the first to analyze hepatic fat in a large population using a technique called proton magnetic resonance spectroscopy - the most sensitive and quantitative noninvasive imaging technique available to measure the amount of fat in the liver. With this technique, they screened more than 2,100 individuals across multiple ethnicities. They then correlated that data with DNA tests from the same people and found the link to the PNPLA3 gene.
The next step in the research is to investigate how the various forms of the PNPLA3 gene affect lipid metabolism.
Other researchers from the McDermott Center involved with the study were lead author Dr. Stefano Romeo, a postdoctoral research fellow; Dr. Alexander Pertsemlidis, assistant professor; Dr. Chao Xing, assistant professor of clinical sciences; and Julia Kozlitina, a graduate student participating in a joint program between Southern Methodist University and UT Southwestern. Researchers from Perlegen Sciences, Lawrence Berkeley National Laboratory and the UT Health Science Center at Houston also were involved.
The research was funded by the Donald W. Reynolds Foundation, the National Institutes of Health and the Department of Energy.
The University of Texas Southwestern Medical Center at Dallas
"A single variation in the PNPLA3 gene was strongly associated with hepatic fat content, even after adjusting for other factors, such as obesity, diabetes status and alcohol intake," said senior study author Dr. Helen Hobbs, director of the Eugene McDermott Center for Human Growth and Development and an investigator for the Howard Hughes Medical Institute at UT Southwestern.
"Sequence variations in this gene explain much of the increased propensity of Hispanics to accumulate excess liver fat," she said.
Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries, and its incidence is growing. Previous UT Southwestern research has shown that it may affect as many as one-third of adults in America.
"The gene variations we have identified might provide a way to predict who is most at risk for developing fatty liver disease and liver injury in response to environmental stresses such as obesity or infection," said Dr. Jonathan Cohen, professor of internal medicine in the McDermott Center and one of the authors of the study.
NAFLD results from the accumulation of triglycerides in the liver and is associated with metabolic disorders such as insulin resistance, obesity, diabetes and high cholesterol - many of the conditions that contribute to heart disease. It can also lead to liver inflammation, cirrhosis and liver cancer. Approximately 10 percent of liver transplants performed in the U.S. are for cirrhosis related to NAFLD, according to the researchers.
Treatments for NAFLD include weight loss, exercise, reducing alcohol intake and improved diabetes control.
"Knowing who is at increased risk of developing liver disease could aid physicians in encouraging their patients to make lifestyle changes or take other preventive measures to help mitigate their underlying genetic risk for the disorder," said Dr. Cohen, holder of the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.
The new findings come out of the Dallas Heart Study, an 8-year-old groundbreaking investigation of cardiovascular disease that involves a large multiethnic group of participants. The
$12 million study investigates the links between genetics, lifestyle and the risks for heart disease.
As part of the Dallas Heart Study, more than 3,500 individuals from Dallas County provided blood samples in 2000 for DNA isolation and other tests. Each participant also underwent multiple body scans with magnetic resonance imaging and computed tomography to examine the heart and other organs. Along with discovering new genetic ties to differences in blood levels of cholesterol and triglycerides, the researchers have used this information to identify new drug targets for the prevention and treatment of heart disease.
Data-gathering for the new study on fatty liver disease took advantage of a unique aspect of the Dallas Heart Study. Researchers with the study were the first to analyze hepatic fat in a large population using a technique called proton magnetic resonance spectroscopy - the most sensitive and quantitative noninvasive imaging technique available to measure the amount of fat in the liver. With this technique, they screened more than 2,100 individuals across multiple ethnicities. They then correlated that data with DNA tests from the same people and found the link to the PNPLA3 gene.
The next step in the research is to investigate how the various forms of the PNPLA3 gene affect lipid metabolism.
Other researchers from the McDermott Center involved with the study were lead author Dr. Stefano Romeo, a postdoctoral research fellow; Dr. Alexander Pertsemlidis, assistant professor; Dr. Chao Xing, assistant professor of clinical sciences; and Julia Kozlitina, a graduate student participating in a joint program between Southern Methodist University and UT Southwestern. Researchers from Perlegen Sciences, Lawrence Berkeley National Laboratory and the UT Health Science Center at Houston also were involved.
The research was funded by the Donald W. Reynolds Foundation, the National Institutes of Health and the Department of Energy.
The University of Texas Southwestern Medical Center at Dallas
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Antibiotics Metabolism Glioblastoma Chronic Kidney Disease Pollution Gravitational Wave Genomics Cell Phone Menopause Mitochondrial Human Brain Learning Cardiomyopathy Stroke Patients Sea Ice Gastric Bypass Rheumatoid Arthritis Neuroticism Amino Acids Cosmic Dust Parkinson’s Disease Smart-1 Child Abuse Shark Attack Ice Shelf
See More: Science News Tags
Liver Disease Current Events and Liver Disease News RSSGenetically engineered mice yield clues to 'knocking out' cancer
Deleting two genes in mice responsible for repairing DNA strands damaged by oxidation leads to several types of tumors, providing additional evidence that such stress contributes to the development of cancer.
Young offenders' health critical to rehabilitation
The physical and mental health needs of juvenile offenders should be treated as a priority if offenders held in detention have any real hope of rehabilitation, according to new research from the University of Adelaide, Australia.
Good news for some hard-to-treat hepatitis C patients
In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment.
What is the role of reactive oxygen species in ethanol-mediated cell death of polarized hepatic cells?
Liver disease that results as a consequence of alcohol abuse is a major medical problem worldwide. Ethanol consumption leads to a variety of liver alterations including the accumulation of fat, inflammation of the liver, as well as the presence of scar tissue.
NEJM Study Points to New Era in Hepatitis C Treatment
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Scientists explain how 'death receptors' designed to kill our cells may make them stronger
It turns out that from the perspective of cell biology, Nietzsche may have been right after all: that which does not kill us does make us stronger.
Liver disease 'shrunk' by blood-pressure drug
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.
Environmental pollution increases the risk of liver disease
A new study is the first to show that there is a previously unrecognized role for environmental pollution in liver disease in the general U.S. adult population.
p90RSK: A new therapeutic target for liver fibrosis?
Cirrhosis is a world wide, bad prognosis liver disease and characterized by excessive collagen deposition and liver function damage.
Hyperferritinemia is another surrogate marker of advanced liver disease
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients.
More Liver Disease Current Events and Liver Disease News Articles
 |
The Liver Book: A Comprehensive Guide to Diagnosis, Treatment, and Recovery by Sanjiv Chopra (Author) It is the portal to total body wellness, the great purifier, and the only human organ that can regenerate itself. But what you don't know about the liver can hurt you! Now, in this complete and authoritative guide that anyone can use and understand, Dr. Sanjiv Chopra explains: The what, where, how, and why of the liver and its miraculous functions |
 |
Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer (Author) In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition, this comprehensive handbook reveals cutting-edge research on the dangers of hepatitis C, one of the world's fasting-growing microbial threats. |
 |
The Liver Book by Atria Books This book tells you all that you ever wanted to know about the liver, its functions and all the diseases and disorders connected with it. Liver disease afflicts millions of people worldwide, ranging from a mild, reversible illness to advanced disease with the potential for myriad and even life-threatening complications. Dr. Sanjiv Chopra's Liver Book acts like a comprehensive guide to the diagnosis, treatment and recovery from liver diseases. |
 |
Holistic Approach to Liver Diseases by Jean Grandoit (Author) |
 |
Native Remedies Liver Dr. for Ongoing Liver Health (50ml) by Native Remedies Liver Dr is a 100% natural, safe and proven herbal remedy for ongoing liver health. Liver Dr. contains herbs known for their ability to maintain healthy liver functioning. It also helps the liver resist damage from toxins and disease, thereby improving overall systemic health. Apart from their beneficial effect on the liver, the herbs chosen for Liver Dr. also have other important therapeutic benefits, which further contribute to a healthy body and better quality of life. Use Liver Dr. to improve functioning of the liver and promote health; prevent problems associated with a sluggish liver; help treat liver disease and prevent further damage to the liver in diseases like viral hepatitis, cirrhosis, fatty liver, hemochromatosis, Alpha-1 antitrypsin deficiency and Wilson¿s disease;... |
 |
The Liver Disorders and Hepatitis Sourcebook (Sourcebooks) by Howard Worman (Author) The latest information on living with and treating liver disorders The Liver Disorders and Hepatitis Sourcebook, Revised Edition, gives you frank assessments of the latest therapies and drugs. It also provides advice on how you can navigate the day-to-day challenges of living with a liver disorder, and diet and nutrition guidelines, including the truth about the effectiveness of herbal remedies and liver-cleansing diets. |
 |
Livers & Heart Disease by Absolutely Kosher |
 |
PetAlive Immunity and Liver Support for Protection Against Disease (60 Caps) by PetAlive Immunity & Liver Pet Immune System Booster Restores liver health and immune functioning in pets for natural protection against disease. |
 |
Zakim and Boyer's Hepatology: A Textbook of Liver Disease, 2-Volume Set (Hepatology (Zakim)) by Thomas D. Boyer MD (Author), Theresa L. Wright MD (Author), Michael P. Manns MD (Author) Long considered the defining work in Hepatology, this trusted 2-volume masterwork has been refocused to zero in on just the clinical knowledge you need to provide today’s best patient care. The most comprehensive text on the subject, this book is still thoroughly grounded in basic science—but now that science is focused on the most clinically relevant developments. Find definitive coverage of all aspects of liver disease in a new full-color format that keeps pace with your evolving practice.* Covers all liver diseases currently seen in clinical practice—in two clinically focused volumes. * Replaces previous editions’ basic science section with the new, more concise "Pathophysiology of Therapeutic Targets" section. * Highlights key references, all current and up to date, to help... |
 |
Drug-Induced Liver Disease by Taylor & Francis Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines. |
| © 2009 BrightSurf.com |